New antibody combo aims to keep bone cancer at bay
NCT ID NCT02502786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a humanized antibody called Hu3F8 combined with GM-CSF (a drug that boosts the immune system) in children and young adults with recurrent osteosarcoma, a type of bone cancer. The goal is to see if this treatment can extend the time before the cancer returns or prevent relapse altogether. The study enrolls 46 participants who are already in remission after a recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
humanized antibody 3F8 (Hu3F8) and GM-CSF
What this could lead to
If it works, this could help keep recurrent osteosarcoma in remission longer and delay or prevent the cancer from coming back.
What could go wrong
This is a small, early-phase trial (46 participants) with no control group, so results may not be conclusive. The treatment may cause side effects and might not prevent relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Los Angeles (Data Collection Only)
Los Angeles, California, 90027, United States
-
MD ANDERSON CANCER CENTER (Data Collection Only)
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States